Multiple drug resistant tuberculosis: Aetiology, diagnosis and outcome

British Medical Bulletin

Volumn 54, Issue 3, 1998, Pages 569-578

  Eltringham, I J ^a   Drobniewski, F ^a  

^a Dulwich Community Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE TRANSMISSION; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0031782118     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011711     Document Type: Review

References (29)

1. Watson JM, Maguire HC. PHLS work on the surveillance and epidemiology of tuberculosis. CDR Rev 1997; 8: 110-2
2. Coker R, Miller R. HIV associated tuberculosis. BMJ 1997; 314: 1847
3. Drobniewski F. Is death inevitable with multiresistant TB plus HIV infection? Lancet 1997; 349: 71-2
4. Handysides S. Tuberculosis remains "the captain of all these men of death'. CDR Rev 1997; 8: R105
5. Mitchison D .Understanding the chemotherapy of tuberculosis-current problems. J Antimicrob Chemother 1992; 29: 477-93
6. Ormerod LP. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Subcommittee of the British Thoracic Society. Thorax 1990; 45: 403-8
7. Gangadharam PRJ. Drug resistance in mycobacteria. Baron Rouge, FL: CRC, 1984; 53-75
8. Warburton ARE, Jenkins PA, Waight PA, Watson JM. Drug resistance in initial isolates of Mycobacterium tuberculosis in England and Wales 1982-1991. Commun Dis Rep 1993; 13: 175-9
9. Drobniewski F, Yates MD. Multiple drug resistant tuberculosis. J Clin Micro 1997; 50: 89-2
10. Wenger PN, Otten J, Breeden A, Orfas D, Beck-Sague CM, Jarvis WR. Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995; 345: 235-40
11. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-91
12. Telenti A, Imboden P, Marchasi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 431: 647-50
13. Drobniewski FA, Pozniak AL. Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Br J Hosp Med 1996; 56: 204-8
14. De Beenhouwer H, Lhiang G, James G et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tubercle Lung Dis 1995; 76: 426-9
15. Scorpio A, Lindholm-Levy P, Heifets L et al. Characterization of pyrazinamide resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-3
16. Sreevatsan S, Stockbauer K, Pan X et al. Ethambutol resistance in Mycobacterium tuberculosis; critical role of embB mutations. Antimicrob Agents Chemother 1997; 41: 1677-81
17. Jacobs WR, Barletta RG, Udani R et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by use of luciferase reporter phages. Science 1993; 260: 819-23
18. Wilson SM, Al-Suwaidi Z, McNerney et al. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nat Med 1997; 3: 465-8
19. Roth A, Schaberg T, Mauch H. Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Eur Respir J 1997; 10: 1877-90
20. Noordhoek GT, Kolk AHJ, Bjune G et al. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 1994; 32: 277-84
21. Nitta AT, Iseman MD, Newell JD, Madsen LA, Goble M. Artificial pneumoperitoneum in the treatment of pulmonary tuberculosis. Clin Infect Dis 1993; 16: 219-22
22. Onyebujoh PC, Abdulmumini T, Robinson S, Rook GA, Stanford JL. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 1995; 89: 199-207
23. Corlan E, Marcia C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. Respir Med 1997; 91: 13-9
24. Corlan E, Marcia C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 1997; 91: 21-9
25. Durman P. Stanford Rook's 'miracle cure' for TB fails. The Times (London) 1 October 1997
26. Condos R, Rom WN, Schluger NW. Treatment of multidrug resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349: 1513-5
27. Raviglione MC, Dye C, Schmidt S et al. Assessment of worldwide tuberculosis control. Lancet 1997; 350: 624-9
28. Drobniewski FA, Pablos-Mendez A, Raviglione MC. Epidemiology of tuberculosis in the world. Semin Respir Crit Care Med 1997; 18: 419-29
29. Conn DL, Bustreo F, Raviglione MC. Drug resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997; 24 (suppl 1): S121-30